Related Experiment Videos
OSI-461 (OSI)
1INSERM 590, University Claude Bernard Lyon 1, 8 Avenue Rockefeller, 69373 Lyon, France. fgalma@rockefeller.univ-lyon1.fr
Current Opinion in Investigational Drugs (London, England : 2000)
|July 10, 2004
Summary
OSI-461, a potent exisulind analog, is being investigated for cancer and inflammatory bowel disease. Clinical trials are underway for chronic lymphocytic leukemia, Crohn
Area of Science:
- Oncology
- Gastroenterology
Background:
- OSI Pharmaceuticals is developing OSI-461, a potent analog of exisulind.
- The compound shows potential for treating cancer and inflammatory bowel disease.
Purpose of the Study:
- To evaluate OSI-461 in clinical trials for various conditions.
- To determine the efficacy of OSI-461 in treating chronic lymphocytic leukemia, Crohn's disease, and hormone-refractory prostate cancer.
Main Methods:
- Phase II clinical trials were initiated in August 2001 for chronic lymphocytic leukemia.
- A pilot Phase II study for Crohn's disease commenced in July 2002.
- Hormone-refractory prostate cancer was selected as a lead indication by October 2002.
Main Results:
- OSI-461 entered Phase II trials for chronic lymphocytic leukemia in August 2001.
- A pilot Phase II study for Crohn's disease began in July 2002.
- Hormone-refractory prostate cancer was identified as a lead indication by October 2002.
Conclusions:
- OSI-461 is under active clinical investigation for multiple indications.
- The compound is being explored for its therapeutic potential in oncology and inflammatory bowel disease.